Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 10-K Report Annual Report
  2. 8-K Event Results of operations
  3. SC 13G/A Stake Amended Statement of Ownership
  4. 8-K Event Regulation FD disclosure
  5. SC 13G/A Stake Amended Statement of Ownership
  6. SC 13G/A Stake Amended Statement of Ownership
  7. 4 Planned sale EVP, Chief Scientific Officer sold 2,275 shares at an average $28.87 ($65,682)
  8. SC 13G/A Stake Amended Statement of Ownership
  9. 144 Insider Sale of Securities
  10. 4 Open-market sale President and CEO sold 19,223 shares at $29.46 ($566,310)
  11. 4 Open-market sale EVP, Chief Medical Officer sold 5,843 shares at $29.46 ($172,135)
  12. 4 Open-market sale EVP, Chief Scientific Officer sold 5,532 shares at $29.46 ($162,973)
  13. 4 Open-market sale EVP, Chief Financial Officer sold 5,365 shares at $29.46 ($158,053)
  14. 4 Open-market sale EVP, Chief Business Officer sold 3,877 shares at $29.46 ($114,216)
  15. 4 Open-market sale EVP, General Counsel sold 3,805 shares at $29.46 ($112,095)
  16. 4 Open-market sale EVP, Chief Technical Officer sold 4,608 shares at an average $29.50 ($135,954)
  17. 8-K Event Results of operations · Regulation FD disclosure · Other events
  18. 4 Option exercise EVP, Chief Scientific Officer acquired 3,500 shares (option exercise)
  19. 4 Option exercise EVP, Chief Medical Officer acquired 3,187 shares (option exercise)
  20. 4 Option exercise President and CEO acquired 7,848 shares (option exercise)

Page 10 of 37 · 725 filings